Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger MYND-type containing 8 (ZMYND8)
- Target
- ZMYND8
- Molecular classification
- Chromatin reader protein, Transcription regulator, Epigenetic regulator, Zinc finger protein (MYND-type)
01
Overview
Zinc finger MYND-type containing 8 (ZMYND8) is a human chromatin-associated protein characterized by a MYND-type zinc finger, a bromodomain, and a plant homeodomain (PHD) finger. It acts as an epigenetic "reader," recognizing specific acetylated lysine residues on histone tails—particularly H3K14ac and H4K16ac—thereby regulating transcription, genome stability, and DNA double-strand break repair. ZMYND8 interacts with DNA repair machinery at damaged chromatin and collaborates with other zinc finger proteins and PARP1 to promote homologous recombination. Reduced or epigenetically silenced expression of ZMYND8 has been linked to a worse prognosis and increased genomic instability in cancers, positioning it as a potential tumor suppressor and biomarker in oncology[1][6][8][10].
- Other names
- ZMYND8RACK7 (Receptor for Activated C Kinase 7)BRAM1 (Bromodomain- and PHD finger-containing protein 1, former name; less common)
02
Mechanism of action
Chromatin reader-binding to acetylated histone lysine residues, regulating gene expression and DNA damage response; Protein–protein interaction via MYND domain, recruiting other DNA repair or chromatin-associated factors
03
Biological functions
Regulation of DNA-templated transcriptionGenome stability maintenanceDNA damage repairChromatin remodelingCell proliferation and differentiation
04
Disease associations
Cancer (notably colorectal and other solid tumors)Genome instability-related disorders
05
Safety considerations
No direct safety concerns currently established for ZMYND8-targeted interventions; off-target effects common to chromatin modifier targeting may be relevant
06
Interacting drugs
No specific drugs directly targeting ZMYND8 are currently approved; however, its bromodomain reader function suggests potential for epigenetic drug targeting
07
Biomarkers
ZMYND8 expression as a prognostic marker in colorectal cancer and potentially other cancers
Beyond the preview
Go deeper on Zinc finger MYND-type containing 8 (ZMYND8).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger MYND-type containing 8 (ZMYND8).